Filing Details

Accession Number:
0001022079-16-000229
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-03 16:21:42
Reporting Period:
2016-03-01
Filing Date:
2016-03-03
Accepted Time:
2016-03-03 16:21:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1022079 Quest Diagnostics Inc DGX Services-Medical Laboratories (8071) 161387862
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222679 E Michael Prevoznik C/O Quest Diagnostics Incorporated
3 Giralda Farms
Madison NJ 07940
Svp & General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-03-01 1,994 $67.01 47,317 No 4 A Direct
Common Stock Disposition 2016-03-01 685 $67.01 46,632 No 4 F Direct
Common Stock Disposition 2016-03-01 919 $66.51 45,713 No 4 F Direct
Common Stock Disposition 2016-03-01 3,532 $68.19 42,181 No 4 S Direct
Common Stock Disposition 2016-03-01 283 $68.62 41,905 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 F Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,775 Indirect 401K
Footnotes
  1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2013, approved in accordance with the requirements of Rule 16b-3(d).
  2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.
  3. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares.
  4. The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 8, 2014.
  5. This transaction was executed in multiple trades at prices ranging from $67.57 to $68.5415. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. This transaction was executed in multiple trades at prices ranging from $68.6200 to $68.6207. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  7. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
  8. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.